Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenalidomide plus reduced dose CHOP combined with rituximab chemotherapy followed by lenalidomide maintenance therapy in elderly patients with diffuse large B cell lymphoma

Next Previous
Search
Trial Profile

Lenalidomide plus reduced dose CHOP combined with rituximab chemotherapy followed by lenalidomide maintenance therapy in elderly patients with diffuse large B cell lymphoma

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms RELOAD Study

    • Most Recent Events

    • 23 Sep 2019 Planned End Date changed to 30 Sep 2024.
    • 23 Sep 2019 Planned primary completion date changed to 30 Sep 2024.
    • 23 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top